Editorial: MYC as a disease target beyond cancer

Whitfield, Jonathan

dc.contributor	Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author	Whitfield, Jonathan
dc.date.accessioned	2024-10-15T10:28:52Z
dc.date.available	2024-10-15T10:28:52Z
dc.date.issued	2024-08-22
dc.identifier.citation	Whitfield JR. Editorial: MYC as a disease target beyond cancer. Front Cell Dev Biol. 2024 Aug 22;12:1467372.
dc.identifier.issn	2296-634X
dc.identifier.uri	https://hdl.handle.net/11351/12066
dc.description	Non-oncologic diseases; Targeting; Transcription factor
dc.language.iso	eng
dc.publisher	Frontiers Media
dc.relation.ispartofseries	Frontiers in Cell and Developmental Biology;12
dc.rights	Attribution 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/
dc.source	Scientia
dc.subject	Malalties - Tractament
dc.subject	Factors de transcripció - Inhibidors
dc.subject.mesh	Disease
dc.subject.mesh	/drug therapy
dc.subject.mesh	Proto-Oncogene Proteins c-myc
dc.subject.mesh	Transcription Factors
dc.subject.mesh	/antagonists & inhibitors
dc.title	Editorial: MYC as a disease target beyond cancer
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	10.3389/fcell.2024.1467372
dc.subject.decs	enfermedad
dc.subject.decs	/farmacoterapia
dc.subject.decs	proteínas protooncogénicas c-myc
dc.subject.decs	factores de transcripción
dc.subject.decs	/antagonistas & inhibidores
dc.relation.publishversion	https://doi.org/10.3389/fcell.2024.1467372
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.audience	Professionals
dc.contributor.organismes	Institut Català de la Salut
dc.contributor.authoraffiliation	[Whitfield JR] Models of Cancer Therapies Laboratory, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid	39239562
dc.identifier.wos	001306618300001
dc.rights.accessrights	info:eu-repo/semantics/openAccess